Bioptimus’ H-optimus-0 Model Now Integrated with Proscia’s Concentriq® for Fast AI Development Bioptimus, a leading French AI startup, has announced the integration of its H-optimus-0 foundation model into Proscia’s Concentriq® Embeddings platform. With 1.1 billion parameters, H-optimus-0 is the largest…
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing…
Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100 per sample, marking a significant step forward in large-scale, unbiased…
NUCLIDIUM Announces First Patient Imaged in Phase 1 Study of ⁶¹Cu Radiotracer for Prostate Cancer NUCLIDIUM has successfully imaged the first patient in its Phase 1 clinical trial evaluating ⁶¹Cu-NuriPro™ (⁶¹Cu-NODAGA-PSMA I&T), a radiotracer designed to safely and accurately diagnose…
Celltrion has announced two-year findings from a post-hoc analysis of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC), presented at United European Gastroenterology (UEG) Week 2024 in Vienna. The analysis shows that dose escalation of subcutaneous infliximab (CT-P13 SC) is effective for…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has shared positive results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, an investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) during their first…
Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has launched Medidata Rave Lite, an extension of its flagship clinical research software, Medidata Rave EDC. Designed specifically for Phase I and IV…
ClearB Therapeutics Licenses Novel Saponin Adjuvant TQL-1055, to Present Hepatitis B Vaccine Data at AASLD 2024 ClearB Therapeutics, a company focused on developing therapeutic vaccines for a functional cure of Hepatitis B, has licensed the novel saponin-based adjuvant TQL-1055 from…
Life Sciences Experts to Explore Global Collaboration, AI, and Clinical Trial Innovation at DIA Canada Annual Meeting The upcoming DIA Canada Annual Meeting, taking place on November 14-15 in Gatineau, Quebec, will gather life sciences leaders to discuss Canada’s precision…
Clarametyx Biosciences Moves Forward with Phase 2a Study of CMTX-101 for Cystic Fibrosis Infections Clarametyx Biosciences, Inc. has successfully completed the Phase 1b portion of its clinical trial for CMTX-101, a novel immune-enabling antibody therapy aimed at treating pulmonary infections…
Kezar Life Sciences Updates on Clinical Trials for Zetomipzomib Kezar Life Sciences, Inc. (Nasdaq: KZR), a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases, has provided important updates on its clinical trials. The Independent Data Monitoring Committee (IDMC)…
Evernorth and Transcarent Collaborate to Deliver Unmatched Cancer Care, Navigation, and Support Services Starting January 1, 2025 Transcarent, known as the One Place for Health and Care, has been selected to power Evernorth Health Services’ new Oncology Benefit Services program.…